ZDA
RPRX

Zweig-DiMenna Associates’s Repros Therapeutics Inc. RPRX Stock Holding History

Zweig-DiMenna Associates’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-15,000
Closed -$402K – 352
2013
Q3 		$402K Buy
+15,000
New +$321K 0.02% 162

Other funds holding RPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Zweig-DiMenna Associates's RPRX Position: Q4 2013 in Review

Zweig-DiMenna Associates sold out of Repros Therapeutics Inc. (RPRX) in Q4 2013, closing a stake of 15,000 shares — an estimated $402K sold.

Zweig-DiMenna Associates first reported a position in RPRX in Q3 2013 and held it in 1 quarter. The position peaked at $402K in Q3 2013. 79 funds tracked by Wall St. Rank hold RPRX as of Q4 2013.

  • Zweig-DiMenna Associates reported no remaining Repros Therapeutics Inc. position as of Q4 2013 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 15,000 Repros Therapeutics Inc. shares in Q4 2013, an estimated $402K.
  • Zweig-DiMenna Associates first reported a position in Repros Therapeutics Inc. in Q3 2013 and held it in 1 quarter.
  • Zweig-DiMenna Associates's Repros Therapeutics Inc. position peaked at $402K in Q3 2013.
  • 79 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q4 2013.

Based on Zweig-DiMenna Associates's 13F filing for Q4 2013, filed 11 Feb 2014.